

15. (New) The method of claim 14 wherein, after closing said surgical opening, said solution consisting essentially of taurultam is administered to said patient by installation or intravenous infusion.

16. (New) The method of claim 13, further including the step of additionally administering a solution consisting essentially of taurultam to said patient prior to forming said surgical opening in said patient's abdomen.

17. (New) The method of claim 13, wherein performing said surgery on said patient includes introducing a trocar tube into said patient during laparoscopic tumor surgery so as to conduct laparoscopic tumor surgery utilizing said trocar tube.

18. (New) The method of claim 17 wherein during said surgery, said administering said solution consisting essentially of taurultam to said patient's abdomen is conducted by passing said solution consisting essentially of taurultam through said trocar tube so as to contact internal tissue of the patient with said solution.

19. (New) The method of claim 18 further comprising the step of withdrawing said trocar tube from said patient prior to said closing said surgical opening and prior to said step of additionally administering said solution consisting essentially of taurultam to said patient after closing said surgical opening.

20. (New) The method of claim 13 wherein said solution contains from 2 to 3% by weight said taurultam.

21. (New) The method of claim 20 wherein said solution further contains heparin, a heparin derivative or hyaluronic acid.

22. (New) The method of claim 18 further comprising the step of additionally introducing said solution into said patient prior to said laparoscopic tumor surgery and prior to introducing said trocar tube into said patient.

23. (New) The method of claim 17 wherein said cancerous tumor is selected from the group consisting of oesophagus carcinoma, cardiacarcinoma, malignant degenerative ulcer, stomach carcinoma, antrum carcinoma, corpus carcinoma, malign adenoma of island cells, gall duct carcinoma, distal choledochus carcinoma, pancreas head carcinoma, pancreas papilla carcinoma, pancreas corpus carcinoma, pancreas cauda carcinoma, small intestinal tract carcinoma, large intestinal tract carcinoma, sarcoma, colon malignancy, adeno carcinoma, lymphoma, malign carcinoid, melanoma, rectal carcinoma, ovarial carcinoma, mamma carcinoma, and prostate carcinoma.

24. (New) The method of claim 13 wherein said cancerous tumor is selected from the group consisting of colon cancer, rectal cancer, pancreatic cancer, stomach cancer and lung cancer.

25. (New) The method of claim 13 further comprising administering to said patient 5-fluorouracil (5-FU) at a dosage within a range of about 0.1-1,000 mg.

26. (New) The method of claim 1 further comprising administering to said patient 5-fluorouracil (5-FU) at a dosage within a range of about 0.1-1,000 mg.--

REMARKS

The above amendments are being made to further define the invention. These amendments do not add to or depart from the original disclosure, or constitute prohibited new matter.

Respectfully submitted,

By



George R. Reppe  
Attorney for Applicants  
Registration No. 31,414  
ROTHWELL, FIGG, ERNST & MANBECK, P.C.  
Suite 800, 1425 K St. N.W.  
Washington, D.C. 20005  
Telephone: (202) 783-6040